Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 123 от 154

Активно (без набиране) Фаза 2/3

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

Gastric Cancer Gastroesophageal Junction Adenocarcinoma Gastric Adenocarcinoma

A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.

Начало: 15.01.2022 Край: 01.06.2026 Възраст: от 18 г. Лечение

Australia, Belgium, Czechia +9 ALX Oncology Inc. NCT05002127

Активно (без набиране) Фаза 3

Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

Partial Epilepsy

Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures

Начало: 14.01.2022 Край: 01.11.2026 Възраст: 2–18 г. Лечение

Australia, Germany, Hungary +4 SK Life Science, Inc. NCT05067634

Активно (без набиране) Фаза 1/2

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Advanced Solid Tumor Locally Advanced Solid Tumor Metastatic Solid Tumor Platinum-resistant Ovarian Cancer +9

TransCon IL-2 β/γ is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This is a first-in-human, open-label, Phase 1/2, dose escalation and dose expansion study of TransCon IL-2 β/γ as monotherapy or in combination therapy in adult participants with advanced or metastatic solid tumors. Given the unique PK profile enabled by the TransCon technology, TransCon IL-2 β/γ presents the opportunity to enhance the therapeutic index of current IL-2 therapy.

Начало: 11.01.2022 Край: 01.08.2029 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +7 Ascendis Pharma Oncology Division A/S NCT05081609

Активно (без набиране) Фаза 3

A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

The purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN).

Начало: 04.01.2022 Край: 01.08.2029 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +10 Ionis Pharmaceuticals, Inc. NCT05071300

Активно (без набиране)

A PMCF Study in Patients With Thoracoabdominal Aortic Aneurysms Treated With E-nside TAAA Multibranch Stent Graft System (INNER-B-APAC)

Thoracoabdominal Aortic Aneurysm

The INNER-B-APAC post-market clinical follow-up study is undertaken to demonstrate the safety and clinical performance of the E-nside TAAA Multibranch Stent Graft System used in endovascular treatment of patients with thoracoabdominal aortic aneurysms.

Начало: 01.01.2022 Край: 01.02.2026 Възраст: 18–85 г.

Australia, New Zealand, Thailand JOTEC GmbH NCT05954793

Активно (без набиране) Фаза 2

Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy

Extensive-Stage Small-Cell Lung Cancer

This is a prospective, multi-centre, single arm, phase 2, open label clinical trial of patients with untreated extensive-stage small-cell lung cancer (ES-SCLC) suitable for first-line platinum-based chemotherapy. The aim of the trial is to assess safety, feasibility and describe efficacy of the addition of concurrent thoracic radiotherapy to usual treatment of chemotherapy and immunotherapy (durvalumab) in patients with ES-SCLC.

Начало: 01.01.2022 Край: 28.02.2028 Възраст: от 18 г. Лечение

Australia Trans Tasman Radiation Oncology Group NCT05796089

Активно (без набиране) Фаза 2

A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera

Phlebotomy Dependent Polycythemia Vera

The main purpose of this study is to evaluate the efficacy of sapablursen in reducing the frequency of phlebotomy and in improving quality of life assessments in participants with polycythemia vera.

Начало: 30.12.2021 Край: 01.06.2026 Възраст: 18–90 г. Лечение

Australia, Canada, Poland +2 Ionis Pharmaceuticals, Inc. NCT05143957

Активно (без набиране) Фаза 2

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

Hidradenitis Suppurativa

Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in areas of the skin such as under the breasts, under armpits, inner thighs, groin and buttocks. Despite the clinical benefit anti-tumor necrosis factor (TNF) therapy offers to patients with HS, there remains a significant unmet medical need for patients who fail to achieve adequate benefit with anti-TNF therapy. This study will compare lutikizumab (ABT-981) versus placebo for the treatment of adult participants with moderate to severe HS who have failed anti-TNF therapy. Lutikizumab (ABT-981) is an investigational drug being developed for the treatment of HS. In the Main Study, participants will be put in 1 of 4 groups, called treatment arms. There is a 1 in 4 chance that participants will be assigned to placebo. Around 160 adult participants with moderate to severe HS who have failed anti-TNF therapy will be enrolled in the study at approximately 50 sites worldwide. In the Sub-study, participants will be put in 1 of 2 groups, called treatment arms. Both arms will receive treatment at different dosing intervals. Around 40 adult participants with moderate to severe HS who are naïve to biologic therapy will be enrolled in the study at approximately 20 sites. In the Main Study, participants will receive subcutaneous injections of lutikizumab (ABT-981) or placebo every week for 16 weeks. In the Sub-study, participants will receive subcutaneous injections of lutikizumab (ABT-981) every week for the first 15 weeks, then either every week or every other week for 36 weeks. There will be an optional Long Term Extension (LTE) for participants who completed Week 52 of the Sub-study and, as confirmed by the investigator, have shown a therapeutic benefit to study drug. Participants would then received lutikizumab using the same assigned dosing regimen as that from Period 2 of the Sub-study for an additional 104 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires and diaries.

Начало: 28.12.2021 Край: 01.12.2027 Възраст: от 18 г. Лечение

Australia, Canada, Germany +5 AbbVie NCT05139602

Активно (без набиране) Фаза 2

Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)

Amyotrophic Lateral Sclerosis

A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients with Amyotrophic Lateral Sclerosis (ALS)

Начало: 22.12.2021 Край: 01.01.2029 Възраст: 18–75 г. Лечение

Australia, United States Woolsey Pharmaceuticals NCT05218668

Активно (без набиране) Фаза 2/3

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

Alzheimers Disease Dementia Alzheimers Disease, Familial

To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug improves disease-related biomarkers and slows the rate of progression of cognitive or clinical impairment.

Начало: 22.12.2021 Край: 01.07.2028 Възраст: 18–80 г. Лечение

Argentina, Australia, Brazil +13 Washington University School of Medicine NCT05269394

Активно (без набиране)

A Global Clinical Study Investigating the Safety and Effectiveness of Smith and Nephew's Porous Knee System in Patients Who Need a Total Knee Replacement Due to Degenerative Arthritis, Post-traumatic Arthritis or Inflammatory Arthritis

Osteoarthritis Post-traumatic Arthritis Rheumatoid Arthritis

A clinical trial investigating the safety and effectiveness of Smith and Nephew's FDA-approved Porous Total Knee System, which is used to replace worn away and diseased knee joints. The aim of this study is to show that most patients who receive the Porous Total Knee System have reduced pain, greater mobility and a long-lasting implant post-surgery.

Начало: 21.12.2021 Край: 25.12.2033 Възраст: 18–80 г.

Australia, Canada, Netherlands +2 Smith & Nephew, Inc. NCT05197036

Активно (без набиране) Фаза 3

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

Neuroendocrine Tumors

The purpose of the study is to evaluate the efficacy, safety \& patient-reported outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of treatment compared to best standard of care in patients with well-differentiated aggressive grade 2 and grade 3, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin.

Начало: 21.12.2021 Край: 01.09.2027 Възраст: от 18 г. Лечение

Australia, China, France +7 ITM Solucin GmbH NCT04919226

Активно (без набиране)

Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer

Prostate Cancer

To demonstrate the effectiveness of the SpaceOAR Vue System in reducing late gastrointestinal (GI) toxicity in subjects undergoing Stereotactic Body Radiotherapy (SBRT) to treat prostate cancer.

Начало: 21.12.2021 Край: 01.04.2030 Възраст: от 18 г. Превенция

Australia, France, Germany +6 Boston Scientific Corporation NCT04905069

Активно (без набиране) Фаза 3

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in participants with early-stage non-small cell lung cancer (NSCLC), who have already had surgery or radiation. Participants who are assigned to placebo and stop the study drug because their disease comes back or gets worse have the option to potentially crossover to selpercatinib. Participation could last up to three years.

Начало: 20.12.2021 Край: 01.05.2028 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +27 Eli Lilly and Company NCT04819100

Активно (без набиране) Фаза 2

The DESyne BDS Plus RCT: A Randomized Clinical Trial to Assess the Elixir DESyne BDS Plus Drug Eluting Coronary Stent System for the Treatment of de Novo Native Coronary Artery Lesions

Coronary Artery Disease

The objective of this clinical trial is to confirm the safety, effectiveness and performance of the DESyne BDS Plus Drug Eluting Coronary Stent System (DESyne BDS Plus DECSS) (Test) as compared to the CE Mark approved DESyne X2 Novolimus Eluting Coronary Stent System (DESyne X2 NECSS; DESyne X2) (Control) in the treatment of de novo native coronary artery lesions.

Начало: 15.12.2021 Край: 01.03.2026 Възраст: от 18 г. Лечение

Belgium, Brazil, Czechia +2 Elixir Medical Corporation NCT05033964

Активно (без набиране)

Pectus Excavatum Camouflage

Pectus Excavatum

The clinical study is testing a new treatment for pectus excavatum called "custom-made 3D printed scaffold-based soft tissue reconstruction". The new method uses a combination of the patients own adipocytes (fat cells) with a 3D printed scaffold (PCL Pectus Scaffold) to support soft tissue regeneration in the patient's chest using the body's natural healing processes. The implanted scaffold acts as a resorbable frame to support the growth of cells. The substance used for the scaffold is resorbable, it's similar to the substance used for sutures and stitches, and it's already Therapeutic Goods Administration (TGA) approved for bone reconstruction of the skull. The implanted scaffold degrades over time, leaving the tissue in its place.

Начало: 14.12.2021 Край: 01.01.2026 Възраст: 18–54 г. Друго

Australia BellaSeno Pty Ltd NCT05451108

Активно (без набиране) Фаза 3

Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

Familial Chylomicronemia

The purpose of AROAPOC3-3001 is to evaluate the efficacy and safety of ARO-APOC3 (plozasiran) in adult participants with familial chylomicronemia syndrome (FCS). Participants who have met all eligibility criteria will be randomized to receive 4 doses of plozasiran or matching placebo administered subcutaneously. Participants who complete the randomized period will continue in a 2-year open-label extension period where all participants will receive plozasiran.

Начало: 14.12.2021 Край: 01.04.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +17 Arrowhead Pharmaceuticals NCT05089084

Активно (без набиране) Фаза 3

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).

Ovarian Cancer Carcinoma, Ovarian Epithelial Fallopian Tube Neoplasms

The primary objective is to compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab, with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by the investigator. The hypotheses are that pembrolizumab plus paclitaxel with or without bevacizumab is superior to placebo plus paclitaxel with or without bevacizumab, with respect to PFS per RECIST 1.1 as assessed by the investigator for participants with programmed cell death ligand 1 (PD-L1) positive tumors (Combined Positive Score \[CPS\] ≥1) and that pembrolizumab plus paclitaxel with or without bevacizumab is superior to placebo plus paclitaxel with or without bevacizumab, with respect to PFS per RECIST 1.1 as assessed by the investigator for all participants.

Начало: 13.12.2021 Край: 16.07.2027 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +21 Merck Sharp & Dohme LLC NCT05116189

Активно (без набиране) Фаза 1

A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients

Breast Cancer

This is an open-label, Phase 1b dose escalation and expansion study to determine the maximum tolerated dose (MTD) of OP-1250 in combination with palbociclib (Ibrance®️, Pfizer Inc.). Purpose of study is to evaluate the safety and pharmacokinetic (PK) profile, and estimate the preliminary anti-tumor activity of the combination in adult subjects with hormone receptor-positive (ER+ / HER2-) advanced or metastatic breast cancer (MBC).

Начало: 10.12.2021 Край: 01.03.2026 Възраст: от 18 г. Лечение

Australia Olema Pharmaceuticals, Inc. NCT05266105

Активно (без набиране) Фаза 1/2

NTLA-2002 in Adults With Hereditary Angioedema (HAE)

Hereditary Angioedema

This study will be conducted to evaluate the safety, tolerability, activity, pharmacokinetics, and pharmacodynamics of NTLA-2002 in adults with Hereditary Angioedema (HAE).

Начало: 10.12.2021 Край: 01.07.2026 Възраст: от 18 г. Лечение

Australia, France, Germany +3 Intellia Therapeutics NCT05120830

1 … 121 122 123 124 125 … 154